The partnership includes support for the design of the Phase III trial and assistance in securing external funding.

GSK has licensed its shigella vaccine candidate to Bharat Biotech. The Big Pharma, which has vowed to help Bharat with trial ...

Hyderabad: Vaccine maker Bharat Biotech International Limited (BBIL) has in-licensed pharma giant GSK's under development ...

This collaboration reflects Bharat Biotech’s continued commitment to global public health and equitable vaccine access ...

Under terms of the deal, Bharat Biotech will lead late-stage development and scale-up of the altSonflex1-2-3 Shigella vaccine ...

India also impacted by Shigellosis, a severe form of bacterial diarrhoea that disproportionately affects children under five ...

Cases of "extensively drug-resistant" Shigella bacteria are on the rise and pose a "serious public health threat," the Centers for Disease Control and Prevention warned last month. In February of ...

The Centers for Disease Control and Prevention reported this week that the bacteria Shigella sonnei has become resistant to ciprofloxacin, the antibiotic that used to shorten the illness it caused ...

UK pharma major GSK today revealed that it has licensed its Shigella vaccine candidate, altSonflex1-2-3, to India’s Bharat ...

Five percent of Shigella infections are now resistant to standard antibiotics. This could be a predictor of what’s to come with other bacteria. By Dana G. Smith Multiple strains of the diarrhea ...

Hyderabad-based Bharat Biotech will lead Phase 3 trials, regulatory progress and manufacturing for Shigella vaccine ...

Get Instant Summarized Text (Gist) Lab-grown human intestinal organoids enabled precise mapping of the genes Shigella bacteria require to invade and colonize human gut tissue. Of approximately ...